Clinical Trial Update: Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating the safety and bioactivity of SG1002 in patients with heart failure; current status is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• SG1002

Snippet

Sponsor: Sulfagenix Australia Pty Ltd. | Conditions: Heart Failure | Phase 1, Phase 2 | Status: UNKNOWN